TG Therapeutics (TGTX) AI Stock Analysis

• Market Cap: $4.67B
• Dividend Yield: N/A
• Average Volume (3M): 1.99M
• Price to Earnings (P/E): 10.6
• Beta (1Y): 0.69
• Revenue Growth: 100.88%
• EPS Growth: N/A
• Country: US
• Employees: 352
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 2.43
• Shares Outstanding: 158,759,450
• 10 Day Avg. Volume: 1,485,569
• 30 Day Avg. Volume: 1,990,340
• PEG Ratio: 2.36
• Price to Book (P/B): 19.67
• Price to Sales (P/S): 13.29
• P/FCF Ratio: -107.84
• Enterprise Value/Market Cap: 1.04
• Enterprise Value/Revenue: 9.12
• Enterprise Value/Gross Profit: 10.69
• Enterprise Value/Ebitda: 42.10
• 1Y Price Target: $42.60
• Price Target Upside: 44.75% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 5
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 62 Neutral
• Price Target: $29.00 ▼(-1.46% Downside)

The score is driven by strong operational/guidance momentum (raised BRIUMVI outlook and positive commercial updates) and a low P/E, but capped by weak cash conversion with still-negative operating/free cash flow and by bearish technicals with the stock trading below key moving averages.

Positive Factors

Commercial traction & revenue growth

BRIUMVI delivered sustained commercial uptake with U.S. net sales driving a sharp revenue increase, reflecting expanding prescriber adoption and patient awareness. Durable commercial traction supports multiyear revenue scaling, a larger sales infrastructure, and stronger long-run cash generation if maintained.

Raised guidance and multi-year revenue targets

Management's raised guidance and explicit 2026 revenue targets provide multi-period visibility, signaling confidence in uptake and planning. This structural guidance supports capital allocation for manufacturing, R&D and commercialization and frames expectations for sustainable top-line growth over the next several years.

Improved balance sheet and lower leverage

Equity increases and reduced leverage improve financial flexibility, lowering refinancing and solvency risk. A healthier capital structure enables funding of inventory builds, manufacturing scale-up and R&D without immediate excessive dilution, supporting execution of medium-term commercial and pipeline plans.

Negative Factors

Negative operating and free cash flow

Despite revenue growth, the company remains cash-negative at the operating level, indicating it is not yet self-funding. Persistent negative cash conversion forces reliance on external capital or balance sheet draws, constraining sustainable investment pace and increasing execution risk over the next 2–6 months.

Earnings quality concerns from non-operating items

TTM net income outpacing operating profit and unusually elevated ROE point to one-time or non-operational gains boosting reported earnings. This undermines confidence in repeatable profitability and raises volatility risk if those items reverse, reducing predictability of future cash earnings.

Concentration risk and rising operating spend for scale-up

Revenue remains heavily concentrated in BRIUMVI with limited ex-U.S. sales; at the same time management plans substantial opex and a $100M manufacturing build. This combination raises execution and concentration risk: delays in approvals, manufacturing or international expansion would materially stress cash flow and growth.

TG Therapeutics Business Overview & Revenue Model

Company Description

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. In addition, it has various licensed preclinical programs for BET, interleukin-1 receptor associated kinase-4, and GITR; and collaboration agreements with Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York.

How the Company Makes Money

TG Therapeutics generates revenue primarily through the sale of its therapeutics once they are approved by regulatory agencies and brought to market. The company also engages in partnerships and collaborations with other pharmaceutical companies, which can provide upfront payments, milestone payments, and royalties on sales of products developed through these partnerships. Additionally, TG Therapeutics may receive funding from grants or government programs aimed at supporting the development of innovative therapies. As the company progresses in clinical trials and gains regulatory approvals, its revenue potential increases significantly through market access and sales of its product portfolio.

TG Therapeutics Financial Statement Overview

Summary

Income statement momentum is strong with sharply scaling revenue and high reported profitability, and the balance sheet appears improved with lower leverage. However, cash flow is the major drag: operating cash flow and free cash flow remain negative, and the mix of very high net income alongside negative operating cash flow suggests weaker earnings quality/cash conversion.

Income Statement

Results have improved materially versus prior years, with revenue scaling sharply (2023 surge followed by continued growth into 2024 and 2025-09-30 TTM (Trailing-Twelve-Months)). Profitability is now strong on the surface, supported by very high gross margin and solid operating profitability in the latest periods. The key weakness is earnings quality/volatility risk: net income in TTM is exceptionally high relative to operating profit, suggesting meaningful non-operating items may be driving bottom-line results, making repeatability less certain.

Balance Sheet

The balance sheet strengthened with equity rising substantially in the latest TTM period, bringing leverage down to a more conservative level (debt-to-equity improves meaningfully versus 2024). Assets have expanded alongside the business, and the company is no longer in a highly levered position. Offsetting this, returns on equity are unusually elevated in TTM, which likely reflects one-time or non-operational earnings effects rather than steady capital efficiency, and total debt remains sizable in absolute dollars.

Cash Flow

Cash generation remains the primary weak spot: operating cash flow and free cash flow are still negative across the historical periods provided, including 2025-09-30 TTM (Trailing-Twelve-Months). While the cash burn has improved compared with earlier years and free cash flow growth is positive in TTM, the business is not yet self-funding from operations. The combination of positive net income with negative operating cash flow also signals a disconnect between reported profits and cash conversion.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	531.90M	329.00M	233.66M	2.79M	6.69M	152.00K
Gross Profit	453.87M	290.52M	219.11M	2.52M	5.90M	152.00K
EBITDA	115.24M	49.90M	26.10M	-213.11M	-341.97M	-272.68M
Net Income	447.47M	23.38M	12.67M	-223.81M	-348.10M	-279.38M
Balance Sheet
Total Assets	1.03B	577.69M	329.59M	193.57M	379.63M	625.64M
Cash, Cash Equivalents and Short-Term Investments	131.58M	311.00M	217.51M	161.68M	314.76M	605.43M
Total Debt	253.72M	253.72M	110.80M	83.06M	79.05M	41.98M
Total Liabilities	417.81M	355.33M	169.09M	134.99M	142.48M	106.29M
Stockholders Equity	607.22M	222.36M	160.50M	58.59M	237.15M	519.35M
Cash Flow
Free Cash Flow	-70.24M	-40.56M	-31.41M	-176.18M	-296.04M	-214.86M
Operating Cash Flow	-70.07M	-40.52M	-31.41M	-176.17M	-295.63M	-214.51M
Investing Cash Flow	45.23M	-1.04M	-50.65M	-20.01M	-332.00K	-24.51M
Financing Cash Flow	-96.86M	128.53M	72.70M	-391.00K	41.42M	679.83M

TG Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 29.43
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TGTX, the sentiment is Negative. The current price of 29.43 is below the 20-day moving average (MA) of 30.04, below the 50-day MA of 30.72, and below the 200-day MA of 33.67, indicating a bearish trend. The MACD of -0.09 indicates Negative momentum. The RSI at 43.02 is Neutral, neither overbought nor oversold. The STOCH value of 16.00 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TGTX.

TG Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
JAZZ	64 Neutral	$10.00B	-27.10	-9.06%	―	4.14%	-179.96%
TGTX	62 Neutral	$4.67B	10.59	111.96%	―	100.88%	―
IONS	56 Neutral	$13.39B	-48.31	-39.99%	―	20.39%	34.00%
AXSM	55 Neutral	$9.29B	-39.43	-275.50%	―	65.83%	28.50%
NUVL	54 Neutral	$7.48B	-19.35	-38.79%	―	―	-52.84%
RYTM	53 Neutral	$6.84B	-33.04	-240.36%	―	54.92%	28.47%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

TG Therapeutics Corporate Events

TG Therapeutics Announces Strong 2025 BRIUMVI Revenue Outlook

On January 13, 2026, TG Therapeutics reported unaudited preliminary results showing U.S. BRIUMVI net product revenue of about $182 million for the fourth quarter of 2025 and $594 million for the full year, contributing to approximately $616 million in total global revenue for 2025, underscoring rapid commercial traction in the multiple sclerosis market since launch. For 2026, the company is targeting total global revenue of roughly $875 million to $900 million, driven largely by anticipated U.S. BRIUMVI sales of $825 million to $850 million, alongside planned operating expenses of about $350 million (excluding non-cash compensation) and roughly $100 million tied to scaling subcutaneous BRIUMVI manufacturing, while advancing a series of pivotal and exploratory clinical milestones intended to expand BRIUMVI’s use, support a subcutaneous and consolidated IV dosing strategy, and progress its azer-cel CAR-T program in autoimmune disease, which together aim to reinforce TG Therapeutics’ growth profile and broaden its autoimmune franchise.

The most recent analyst rating on (TGTX) stock is a Hold with a $30.00 price target. To see the full list of analyst forecasts on TG Therapeutics stock, see the TGTX Stock Forecast page.